GREY:IMVIF - Post by User
Post by
Breakthorough1on Jul 27, 2023 1:39pm
113 Views
Post# 35559958
December 28 2020
December 28 2020Has anyone seen this data?:
“We are encouraged by the data generated thus far. Results are consistent with the mechanism of action of our DPX delivery platform demonstrated across prior clinical studies with DPX-based vaccines and cancer immunotherapies,” said Joanne Schindler, Chief Medical Officer at IMV. “By prolonging exposure to antigens, the DPX platform can generate longer lasting antibody titers in humans. This is the hallmark of our DPX platform, and it has the potential to improve the span of protection against COVID-19 including in the most vulnerable populations.”